113 results on '"Entz-Werlé, Natacha"'
Search Results
2. Clinical impact of large genomic explorations at diagnosis in 198 pediatric solid tumors: a monocentric study aiming practical feasibility of precision oncology
- Author
-
Simon, Juliette, Reita, Damien, Guerin, Eric, Lhermitte, Benoit, Weingertner, Noelle, Lefebvre, François, Karanian, Marie, Masliah-Planchon, Julien, Lindner, Veronique, Onea, Alina, Jannier, Sarah, Salmon, Alexandra, Bergthold, Guillaume, Vincent, Florence, Deschuyter, Marlène, Barbaza, Marie-Odile, and Entz-Werlé, Natacha
- Published
- 2024
- Full Text
- View/download PDF
3. Hypoxia-driven heterogeneous expression of α5 integrin in glioblastoma stem cells is linked to HIF-2α
- Author
-
Messé, Mélissa, Bernhard, Chloé, Foppolo, Sophie, Thomas, Lionel, Marchand, Patrice, Herold-Mende, Christel, Idbaih, Ahmed, Kessler, Horst, Etienne-Selloum, Nelly, Ochoa, Charles, Tambar, Uttam K., Elati, Mohamed, Laquerriere, Patrice, Entz-Werle, Natacha, Martin, Sophie, Reita, Damien, and Dontenwill, Monique
- Published
- 2024
- Full Text
- View/download PDF
4. Overcoming the limits of pediatric brain tumor radiotherapy: The use of preclinical 3D models
- Author
-
Czuba, Élodie, Deschuyter, Marlène, Entz-Werlé, Natacha, Noël, Georges, and Burckel, Hélène
- Published
- 2024
- Full Text
- View/download PDF
5. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
- Author
-
Raiser, Patricia, Schleiermacher, Gudrun, Gambart, Marion, Dumont, Benoit, Defachelles, Anne-Sophie, Thebaud, Estelle, Tandonnet, Julie, Pasqualini, Claudia, Proust, Stéphanie, Entz-Werle, Natacha, Aerts, Isabelle, Ndounga-Diakou, Lee A., Petit, Arnaud, Puiseux, Chloe, Khanfar, Camille, Rouger, Jeremie, Mansuy, Ludovic, Benadiba, Joy, Millot, Frédéric, Pluchart, Claire, Laghouati, Salim, Geoerger, Birgit, Vassal, Gilles, Valteau-Couanet, Dominique, and Berlanga, Pablo
- Published
- 2024
- Full Text
- View/download PDF
6. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS
- Author
-
Chaix, Jordane, Schleiermacher, Gudrun, Corradini, Nadège, André, Nicolas, Thebaud, Estelle, Gambart, Marion, Defachelles, Anne-Sophie, Entz-Werle, Natacha, Chastagner, Pascal, De Carli, Émilie, Ducassou, Stéphane, Landman-Parker, Judith, Adam-de-Beaumais, Tiphaine, Larive, Alicia, Michiels, Stefan, Vassal, Gilles, Valteau-Couanet, Dominique, Geoerger, Birgit, and Berlanga, Pablo
- Published
- 2024
- Full Text
- View/download PDF
7. A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors
- Author
-
Marques Da Costa, Maria Eugénia, Zaidi, Sakina, Scoazec, Jean-Yves, Droit, Robin, Lim, Wan Ching, Marchais, Antonin, Salmon, Jerome, Cherkaoui, Sarah, Morscher, Raphael J., Laurent, Anouchka, Malinge, Sébastien, Mercher, Thomas, Tabone-Eglinger, Séverine, Goddard, Isabelle, Pflumio, Francoise, Calvo, Julien, Redini, Francoise, Entz-Werlé, Natacha, Soriano, Aroa, Villanueva, Alberto, Cairo, Stefano, Chastagner, Pascal, Moro, Massimo, Owens, Cormac, Casanova, Michela, Hladun-Alvaro, Raquel, Berlanga, Pablo, Daudigeos-Dubus, Estelle, Dessen, Philippe, Zitvogel, Laurence, Lacroix, Ludovic, Pierron, Gaelle, Delattre, Olivier, Schleiermacher, Gudrun, Surdez, Didier, and Geoerger, Birgit
- Published
- 2023
- Full Text
- View/download PDF
8. All pineal tumors expressing germ cell tumor markers are not necessarily germ cell tumors: histopathological and molecular study of a midline primary intracranial sarcoma DICER1-mutant
- Author
-
Wolf, Thibaut, Coca, Andres Hugo, Weingertner, Noelle, Chenard, Marie Pierre, Meurgey, Alexandra, Reita, Damien, Pencreach, Erwan, Varlet, Pascale, Entz-Werlé, Natacha, and Lhermitte, Benoît
- Published
- 2023
- Full Text
- View/download PDF
9. Pediatric Tumors and Developmental Anomalies: A French Nationwide Cohort Study
- Author
-
Semeraro, Michaela, Fouquet, Cyrielle, Vial, Yoann, Amiel, Jeanne, Galmiche, Louise, Cretolle, Célia, Blanc, Thomas, Jolaine, Valérie, Garcelon, Nicolas, Entz-Werle, Natacha, Pellier, Isabelle, Vérité, Cécile, Sophie Taque, Coulomb, Aurore, Petit, Arnaud, Corradini, Nadège, Bouazza, Naim, Lacour, Brigitte, Clavel, Jacqueline, Brugières, Laurence, Bourdeaut, Franck, and Sarnacki, Sabine
- Published
- 2023
- Full Text
- View/download PDF
10. Challenges in glioblastoma research: focus on the tumor microenvironment
- Author
-
Bikfalvi, Andreas, da Costa, Cristine Alves, Avril, Tony, Barnier, Jean-Vianney, Bauchet, Luc, Brisson, Lucie, Cartron, Pierre Francois, Castel, Hélène, Chevet, Eric, Chneiweiss, Hervé, Clavreul, Anne, Constantin, Bruno, Coronas, Valérie, Daubon, Thomas, Dontenwill, Monique, Ducray, Francois, Entz-Werlé, Natacha, Figarella-Branger, Dominique, Fournier, Isabelle, Frenel, Jean-Sébastien, Gabut, Mathieu, Galli, Thierry, Gavard, Julie, Huberfeld, Gilles, Hugnot, Jean-Philippe, Idbaih, Ahmed, Junier, Marie-Pierre, Mathivet, Thomas, Menei, Philippe, Meyronet, David, Mirjolet, Céline, Morin, Fabrice, Mosser, Jean, Moyal, Elisabeth Cohen-Jonathan, Rousseau, Véronique, Salzet, Michel, Sanson, Marc, Seano, Giorgio, Tabouret, Emeline, Tchoghandjian, Aurélie, Turchi, Laurent, Vallette, Francois M., Vats, Somya, Verreault, Maité, and Virolle, Thierry
- Published
- 2023
- Full Text
- View/download PDF
11. Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model‐based population pharmacokinetic analysis
- Author
-
Hamimed, Mourad, Leblond, Pierre, Dumont, Aurélie, Gattacceca, Florence, Tresch-Bruneel, Emmanuelle, Probst, Alicia, Chastagner, Pascal, Pagnier, Anne, De Carli, Emilie, Entz-Werlé, Natacha, Grill, Jacques, Aerts, Isabelle, Frappaz, Didier, Bertozzi-Salamon, Anne-Isabelle, Solas, Caroline, André, Nicolas, and Ciccolini, Joseph
- Published
- 2022
- Full Text
- View/download PDF
12. An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years
- Author
-
Abou-Chahla, Wadih, Adoue, Daniel, Aladjidi, Nathalie, Armari-Alla, Corinne, Barlogis, Vincent, Bayart, Sophie, Bertrand, Yves, Blanche, Stéphane, Bodet, Damien, Bonnotte, Bernard, Borie, Raphaël, Boutard, Patrick, Boutboul, David, Briandet, Claire, Brion, Jean-Paul, Brouard, Jacques, Carausu, Liana, Castelle, Martin, Cathebras, Pascal, Catherinot, Emilie, Cheikh, Nathalie, Cheminant, Morgane, Cohen-Beaussant, Sarah, Comont, Thibault, Couderc, Louis-Jean, Cougoul, Pierre, Couillault, Gérard, Crevon, Lionel, Demonchy, Elisa, Deville, Anne, Devoldere, Catherine, Dore, Eric, Dulieu, Fabienne, Durieu, Isabelle, Entz-Werle, Natacha, Fieschi, Claire, Fouyssac, Fanny, Frange, Pierre, Gajdos, Vincent, Galicier, Lionel, Gandemer, Virginie, Gardembas, Martine, Gaud, Catherine, Grosbois, Bernard, Guffroy, Aurélien, Guitton, Corinne, Guillerm, Gaëlle, Hachulla, Eric, Hamidou, Mohamed, Haro, Sophie, Hatchuel, Yves, Hermine, Olivier, Hoarau, Cyrille, Hot, Arnaud, Humbert, Sébastien, Jaccard, Arnaud, Jais, Jean-Philippe, Jannier, Sarah, Jacquot, Serge, Jaussaud, Roland, Jeandel, Pierre-Yves, Jeziorski, Eric, Kebaili, Kamila, Korganow, Anne-Sophie, Lambotte, Olivier, Lanternier, Fanny, Larroche, Claire, Launay, David, Le Moigne, Emmanuelle, Le Quellec, Alain, Le Moing, Vincent, Lebranchu, Yvon, Lecuit, Marc, Lefèvre, Guillaume, Lelièvre, Jean-Daniel, Lemal, Richard, Li-Thiao-Te, Valérie, Lortholary, Olivier, Luca, Luminita, Mallebranche, Coralie, Malphettes, Marion, Marie-Cardine, Aude, Martin-Silva, Nicolas, Masseau, Agathe, Mazingue, Françoise, Merlin, Etienne, Michel, Gérard, Millot, Frédéric, Miot, Charline, Monlibert, Béatrice, Monpoux, Fabrice, Moshous, Despina, Mouthon, Luc, Münzer, Martine, Navarro, Robert, Neven, Bénédicte, Nouar, Dalila, Nove-Josserand, Raphaële, Oksenhendler, Eric, Ouachée-Chardin, Marie, Pagnier, Anne, Pasquet, Marlène, Pellier, Isabelle, Perel, Yves, Perlat, Antoinette, Piguet, Christophe, Plantaz, Dominique, Rivière, Sophie, Roblot, Pascal, Rohrlich, Pierre-Simon, Royer, Bruno, Salle, Valéry, Sarrot-Reynauld, Françoise, Servettaz, Amélie, Stephan, Jean-Louis, Schleinitz, Nicolas, Sokol, Harry, Suarez, Felipe, Swiader, Laure, Taque, Sophie, Thomas, Caroline, Tournilhac, Olivier, Thumerelle, Caroline, Vannier, Jean-Pierre, Viallard, Jean-François, Alligon, Mickaël, Mahlaoui, Nizar, Courteille, Virginie, Costes, Laurence, Afonso, Veronica, Randrianomenjanahary, Philippe, de Vergnes, Nathalie, Ranohavimparany, Anja, Vo, Duy, Hafsa, Inès, Bach, Perrine, Benoit, Vincent, Garcelon, Nicolas, and Fischer, Alain
- Published
- 2022
- Full Text
- View/download PDF
13. Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort
- Author
-
Lankester, Arjan C., Neven, Benedicte, Mahlaoui, Nizar, von Asmuth, Erik G.J., Courteille, Virginie, Alligon, Mikael, Albert, Michael H., Serra, Isabelle Badell, Bader, Peter, Balashov, Dmitry, Beier, Rita, Bertrand, Yves, Blanche, Stephane, Bordon, Victoria, Bredius, Robbert G., Cant, Andrew, Cavazzana, Marina, Diaz-de-Heredia, Cristina, Dogu, Figen, Ehlert, Karoline, Entz-Werle, Natacha, Fasth, Anders, Ferrua, Francesca, Ferster, Alina, Formankova, Renata, Friedrich, Wilhelm, Gonzalez-Vicent, Marta, Gozdzik, Jolanta, Güngör, Tayfun, Hoenig, Manfred, Ikinciogullari, Aydan, Kalwak, Krzysztof, Kansoy, Savas, Kupesiz, Alphan, Lanfranchi, Arnalda, Lindemans, Caroline A., Meisel, Roland, Michel, Gerard, Miranda, Nuno A.A., Moraleda, Jose, Moshous, Despina, Pichler, Herbert, Rao, Kanchan, Sedlacek, Petr, Slatter, Mary, Soncini, Elena, Speckmann, Carsten, Sundin, Mikael, Toren, Amos, Vettenranta, Kim, Worth, Austen, Yeşilipek, Mehmet A., Zecca, Marco, Porta, Fulvio, Schulz, Ansgar, Veys, Paul, Fischer, Alain, and Gennery, Andrew R.
- Published
- 2022
- Full Text
- View/download PDF
14. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
- Author
-
Gaspar, Nathalie, Venkatramani, Rajkumar, Hecker-Nolting, Stefanie, Melcon, Soledad Gallego, Locatelli, Franco, Bautista, Francisco, Longhi, Alessandra, Lervat, Cyril, Entz-Werle, Natacha, Casanova, Michela, Aerts, Isabelle, Strauss, Sandra J, Thebaud, Estelle, Morland, Bruce, Nieto, Adela Cañete, Marec-Berard, Perrine, Gambart, Marion, Rossig, Claudia, Okpara, Chinyere E, He, Cixin, Dutta, Lea, and Campbell-Hewson, Quentin
- Published
- 2021
- Full Text
- View/download PDF
15. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
- Author
-
Italiano, Antoine, Mir, Olivier, Mathoulin-Pelissier, Simone, Penel, Nicolas, Piperno-Neumann, Sophie, Bompas, Emmanuelle, Chevreau, Christine, Duffaud, Florence, Entz-Werlé, Natacha, Saada, Esma, Ray-Coquard, Isabelle, Lervat, Cyril, Gaspar, Nathalie, Marec-Berard, Perrine, Pacquement, Hélène, Wright, John, Toulmonde, Maud, Bessede, Alban, Crombe, Amandine, Kind, Michèle, Bellera, Carine, and Blay, Jean-Yves
- Published
- 2020
- Full Text
- View/download PDF
16. Denosumab for treating aneurysmal bone cysts in children
- Author
-
Raux, Sébastien, Bouhamama, Amine, Gaspar, Nathalie, Brugières, Laurence, Entz-Werlé, Natacha, Mallet, Cindy, Dijoud, Frédérique, Gouin, François, and Marec-Bérard, Perrine
- Published
- 2019
- Full Text
- View/download PDF
17. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study
- Author
-
Gaspar, Nathalie, Occean, Bob-Valéry, Pacquement, Hélène, Bompas, Emmanuelle, Bouvier, Corine, Brisse, Hervé J., Castex, Marie-Pierre, Cheurfa, Nadir, Corradini, Nadège, Delaye, Jessy, Entz-Werlé, Natacha, Gentet, Jean-Claude, Italiano, Antoine, Lervat, Cyril, Marec-Berard, Perrine, Mascard, Eric, Redini, Françoise, Saumet, Laure, Schmitt, Claudine, Tabone, Marie-Dominique, Verite-Goulard, Cécile, Le Deley, Marie-Cécile, Piperno-Neumann, Sophie, and Brugieres, Laurence
- Published
- 2018
- Full Text
- View/download PDF
18. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies
- Author
-
Adoue, Daniel, Aladjidi, Nathalie, Amoura, Zahir, Arlet, Philippe, Armari-Alla, Corinne, Bader-Meunier, Brigitte, Barlogis, Vincent, Bayart, Sophie, Beaurain, Beatrice, Bertrand, Yves, Bienvenu, Boris, Blanche, Stéphane, Bodet, Damien, Bonnotte, Bernard, Borie, Raphaël, Boutard, Patrick, Briandet, Claire, Brion, Jean-Paul, Brito, Carolina, Brouard, Jacques, Catherinot, Emilie, Chandesris, Olivia, Cohen-Beaussant, Sarah, Coignard-Biehler, Hélène, Costes, Laurence, Couderc, Louis-Jean, Couillault, Gérard, Courteille, Virginie, Curlier, Elodie, de Saint Basile, Geneviève, Demeocq, François, de Vergnes, Nathalie, Devoldere, Catherine, Deville, Anne, Donadieu, Jean, Dore, Eric, Dulieu, Fabienne, Durieu, Isabelle, Edan, Christine, Entz Werle, Natacha, Fieschi, Claire, Fouyssac, Fanny, Frange, Pierre, Gajdos, Vincent, Galicier, Lionel, Gandemer, Virginie, Gardembas, Martine, Gaud, Catherine, Grosbois, Bernard, Guillerm, Gaelle, Hachulla, Eric, Hamidou, Mohamed, Héritier, Sébastien, Hermine, Olivier, Hoarau, Cyrille, Hoen, Bruno, Hot, Arnaud, Humbert, Sébastien, Jaccard, Arnaud, Jacquot, Serge, Jais, Jean-Philippe, Jaussaud, Rolland, Jeandel, Pierre-Yves, Jeziorski, Eric, Kebaili, Kamila, Korganow, Anne-Sophie, Labrune, Philippe, Lambotte, Olivier, Lanternier, Fanny, Larroche, Claire, Le Quellec, Alain, Le Moigne, Emmanuelle, Le Moing, Vincent, Lebranchu, Yvon, Lecuit, Marc, Lefevre, Guillaume, Lemal, Richard, Le Moine, Philippe, Li Thiao Te, Valérie, Lortholary, Olivier, Lutz, Patrick, Magerus-Chatinet, Aude, Malphettes, Marion, Marie-Cardine, Aude, Martin Silva, Nicolas, Masseau, Agathe, Massot, Christian, Mazingue, Françoise, Merlin, Etienne, Michel, Gérard, Millot, Frédéric, Minckes, Odile, Monlibert, Béatrice, Monpoux, Fabrice, Moshous, Despina, Mouthon, Luc, Munzer, Martine, Neven, Bénédicte, Nove-Josserand, Raphaëlle, Oksenhendler, Eric, Ouachée-Chardin, Marie, Pagnier, Anne, Pasquali, Jean-Louis, Pasquet, Marlène, Pellier, Isabelle, Perel, Yves, Perlat, Antoinette, Picard, Capucine, Piguet, Christophe, Plantaz, Dominique, Quartier, Pierre, Rieux-Laucat, Frédéric, Roblot, Pascal, Roger, Pierre-Marie, Rohrlich, Pierre-Simon, Royer, Bruno, Salle, Valéry, Sarrot-Reynauld, Françoise, Servettaz, Amélie, Stephan, Jean-Louis, Schleinitz, Nicolas, Suarez, Felipe, Swiader, Laure, Taque, Sophie, Thomas, Caroline, Tournilhac, Olivier, Thumerelle, Caroline, Vannier, Jean-Pierre, Viallard, Jean-François, Fischer, Alain, Provot, Johan, Alcais, Alexandre, and Mahlaoui, Nizar
- Published
- 2017
- Full Text
- View/download PDF
19. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
- Author
-
Mackay, Alan, Burford, Anna, Carvalho, Diana, Izquierdo, Elisa, Fazal-Salom, Janat, Taylor, Kathryn R., Bjerke, Lynn, Clarke, Matthew, Vinci, Mara, Nandhabalan, Meera, Temelso, Sara, Popov, Sergey, Molinari, Valeria, Raman, Pichai, Waanders, Angela J., Han, Harry J., Gupta, Saumya, Marshall, Lynley, Zacharoulis, Stergios, Vaidya, Sucheta, Mandeville, Henry C., Bridges, Leslie R., Martin, Andrew J., Al-Sarraj, Safa, Chandler, Christopher, Ng, Ho-Keung, Li, Xingang, Mu, Kun, Trabelsi, Saoussen, Brahim, Dorra H’mida-Ben, Kisljakov, Alexei N., Konovalov, Dmitry M., Moore, Andrew S., Carcaboso, Angel Montero, Sunol, Mariona, de Torres, Carmen, Cruz, Ofelia, Mora, Jaume, Shats, Ludmila I., Stavale, João N., Bidinotto, Lucas T., Reis, Rui M., Entz-Werle, Natacha, Farrell, Michael, Cryan, Jane, Crimmins, Darach, Caird, John, Pears, Jane, Monje, Michelle, Debily, Marie-Anne, Castel, David, Grill, Jacques, Hawkins, Cynthia, Nikbakht, Hamid, Jabado, Nada, Baker, Suzanne J., Pfister, Stefan M., Jones, David T.W., Fouladi, Maryam, von Bueren, André O., Baudis, Michael, Resnick, Adam, and Jones, Chris
- Published
- 2017
- Full Text
- View/download PDF
20. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial
- Author
-
Piperno-Neumann, Sophie, Le Deley, Marie-Cécile, Rédini, Françoise, Pacquement, Hélène, Marec-Bérard, Perrine, Petit, Philippe, Brisse, Hervé, Lervat, Cyril, Gentet, Jean-Claude, Entz-Werlé, Natacha, Italiano, Antoine, Corradini, Nadège, Bompas, Emmanuelle, Penel, Nicolas, Tabone, Marie-Dominique, Gomez-Brouchet, Anne, Guinebretière, Jean-Marc, Mascard, Eric, Gouin, François, Chevance, Aurélie, Bonnet, Naïma, Blay, Jean-Yves, and Brugières, Laurence
- Published
- 2016
- Full Text
- View/download PDF
21. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents
- Author
-
Bodo, Sahra, Colas, Chrystelle, Buhard, Olivier, Collura, Ada, Tinat, Julie, Lavoine, Noémie, Guilloux, Agathe, Chalastanis, Alexandra, Lafitte, Philippe, Coulet, Florence, Buisine, Marie-Pierre, Ilencikova, Denisa, Ruiz-Ponte, Clara, Kinzel, Miriam, Grandjouan, Sophie, Brems, Hilde, Lejeune, Sophie, Blanché, Hélène, Wang, Qing, Caron, Olivier, Cabaret, Odile, Svrcek, Magali, Vidaud, Dominique, Parfait, Béatrice, Verloes, Alain, Knappe, Ulrich J., Soubrier, Florent, Mortemousque, Isabelle, Leis, Alexander, Auclair-Perrossier, Jessie, Frébourg, Thierry, Fléjou, Jean-François, Entz-Werle, Natacha, Leclerc, Julie, Malka, David, Cohen-Haguenauer, Odile, Goldberg, Yael, Gerdes, Anne-Marie, Fedhila, Faten, Mathieu-Dramard, Michèle, Hamelin, Richard, Wafaa, Badre, Gauthier-Villars, Marion, Bourdeaut, Franck, Sheridan, Eamonn, Vasen, Hans, Brugières, Laurence, Wimmer, Katharina, Muleris, Martine, and Duval, Alex
- Published
- 2015
- Full Text
- View/download PDF
22. Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX).
- Author
-
Leblond, Pierre, Tresch-Bruneel, Emmanuelle, Probst, Alicia, Néant, Nadège, Solas, Caroline, Sterin, Arthur, Boulanger, Thomas, Aerts, Isabelle, Faure-Conter, Cécile, Bertozzi, Anne-Isabelle, Chastagner, Pascal, Entz-Werlé, Natacha, De Carli, Emilie, Deley, Marie-Cécile Le, Bouche, Gauthier, and André, Nicolas
- Subjects
CARDIOVASCULAR disease prevention ,CYCLOOXYGENASE 2 ,DRUG efficacy ,DRUG repositioning ,FLUVASTATIN ,COMBINATION drug therapy ,CLINICAL trials ,NONSTEROIDAL anti-inflammatory agents ,GLIOMAS ,CANCER relapse ,CREATINE kinase ,BRAIN tumors ,CREATINE ,DESCRIPTIVE statistics ,RESEARCH funding ,EVALUATION ,CHILDREN - Abstract
Simple Summary: This study tested the repurposing of two rationally selected, non-anticancer drugs as a way to address the need for less toxic therapeutic options in children with gliomas. The determined recommended phase II dose of fluvastatin in combination with celecoxib in children with gliomas is 6 mg/kg/day (in 14 days on, 14 days off schedule) with a fixed daily dose of celecoxib (from 200 mg to 800 mg depending on weight). The combination is not active in HGG but could be explored as a maintenance treatment in LGG patients to avoid or delay a possible tumor recurrence, which would require a more toxic treatment. This oral strategy with very limited toxicity may be used to gain time and therefore limit treatment-related toxicities in growing children. Given its good safety profile, its low cost and all-oral administration, we think that it could be considered as an option for children with LGG living in low- and middle-income countries. Preclinical data support the activity of celecoxib and fluvastatin in high-grade (HGG) and low-grade gliomas (LGG). A phase I trial (NCT02115074) was designed to evaluate the safety of this combination in children with refractory/relapsed HGG and LGG using four dose levels of fluvastatin with a fixed daily dose of celecoxib. A Continual Reassessment Method was used for fluvastatin dose escalation. Dose-limiting toxicities (DLT) were determined on the first treatment cycle. Twenty patients were included. Ten LGG and ten HGG patients received a median of 3.5 treatment cycles. Two DLTs were reported: one grade 3 maculopapular rash (4 mg/kg dose level) and one grade 4 increase of Creatine Phospho-Kinase (6 mg/kg dose level). We identified the dose of 6 mg/kg/day as the recommended phase II dose (RP2D) of fluvastatin with celecoxib. Four patients with LGG continued treatment beyond 12 cycles because of stable disease, including one patient who received 23 treatment cycles. In children with refractory/relapsed glioma, the RP2D of fluvastatin with celecoxib is 6 mg/kg/day. The long-term stable diseases observed in LGG suggest a possible role of the combination in a maintenance setting, given its good tolerance and low cost for children living in low- and middle-income countries. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances.
- Author
-
Geyer, Lucas, Wolf, Thibaut, Chenard, Marie-Pierre, Cebula, Helene, Schott, Roland, Noel, Georges, Guerin, Eric, Pencreach, Erwan, Reita, Damien, Entz-Werlé, Natacha, and Lhermitte, Benoît
- Subjects
GLIOMAS ,GENE expression ,CANCER patients - Abstract
Simple Summary: The 2021 WHO classification of central nervous system tumors is a histomolecular classification system that takes into account numerous molecular data in order to better stratify patient prognoses and treatments. CDKN2A homozygous deletion appears to be associated with poor prognosis in many types of gliomas. The search for this deletion requires complex techniques. As CDKN2A encodes the p16 protein, a reliable, reproducible, and clinically meaningful IHC stain would be useful as a surrogate test. This study attempts to describe the clinical impacts of p16 immunohistochemical expression in a wide variety of gliomas, as well as its correlation with CDKN2A homozygous deletion. CDKN2A is a tumor suppressor gene encoding the p16 protein, a key regulator of the cell cycle. CDKN2A homozygous deletion is a central prognostic factor for numerous tumors and can be detected by several techniques. This study aims to evaluate the extent to which immunohistochemical levels of p16 expression may provide information about CDKN2A deletion. A retrospective study was conducted in 173 gliomas of all types, using p16 IHC and CDKN2A fluorescent in situ hybridization. Survival analyses were performed to assess the prognostic impact of p16 expression and CDKN2A deletion on patient outcomes. Three patterns of p16 expression were observed: absence of expression, focal expression, and overexpression. Absence of p16 expression was correlated with worse outcomes. p16 overexpression was associated with better prognoses in MAPK-induced tumors, but with worse survival in IDH-wt glioblastomas. CDKN2A homozygous deletion predicted worse outcomes in the overall patient population, particularly in IDH-mutant 1p/19q oligodendrogliomas (grade 3). Finally, we observed a significant correlation between p16 immunohistochemical loss of expression and CDKN2A homozygosity. IHC has strong sensitivity and high negative predictive value, suggesting that p16 IHC might be a pertinent test to detect cases most likely harboring CDKN2A homozygous deletion. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Targeted Apc;Twist Double-Mutant Mice: A New Model of Spontaneous Osteosarcoma That Mimics the Human Disease
- Author
-
Entz-Werlé, Natacha, Choquet, Philippe, Neuville, Agnès, Kuchler-Bopp, Sabine, Clauss, François, Danse, Jean-Marc, Simo-Noumbissie, Pauline, Guérin, Eric, Gaub, Marie-Pierre, Freund, Jean-Noel, Boehm, Nelly, Constantinesco, André, Lutz, Patrick, Guenot, Dominique, and Perrin-Schmitt, Fabienne
- Published
- 2010
- Full Text
- View/download PDF
25. Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications.
- Author
-
Lhermitte, Benoit, Wolf, Thibaut, Chenard, Marie Pierre, Coca, Andres, Todeschi, Julien, Proust, François, Hirsch, Edouard, Schott, Roland, Noel, Georges, Guerin, Eric, Reita, Damien, Chammas, Agathe, Salmon, Alexandra, Martin, Sophie, Dontenwill, Monique, and Entz-Werlé, Natacha
- Subjects
GLIOMA treatment ,GENETIC mutation ,GLIOMAS ,MITOGEN-activated protein kinases ,TUMOR grading - Abstract
Simple Summary: Drugs targeting activating BRAF mutations have transformed the prognosis and treatment of MAPK-pathway-induced cancers. In neuro-oncology, the better knowledge of the MAPK pathway's involvement in gliomagenesis offers hope in a subset of brain cancers where conventional therapies have produced disappointing results. The temptation to use BRAF inhibitors alone or in combination in cerebral mutant tumors is high and is providing survival benefit in trials. Nonetheless, it is currently not clear what kind of gliomas can be treated and when the patient will benefit from these therapies in terms of permanent curability. This review will summarize the up-to-date literature regarding BRAF-altered gliomas, their molecular diagnosis, their prognosis, their associated molecular alterations, and how potentially treat those tumors. Over the last few decades, deciphering the alteration of molecular pathways in brain tumors has led to impressive changes in diagnostic refinement. Among the molecular abnormalities triggering and/or driving gliomas, alterations in the MAPK pathway reign supreme in the pediatric population, as it is encountered in almost all low-grade pediatric gliomas. Activating abnormalities in the MAPK pathway are also present in both pediatric and adult high-grade gliomas. Across those alterations, BRAF p.V600E mutations seem to define homogeneous groups of tumors in terms of prognosis. The recent development of small molecules inhibiting this pathway retains the attention of neurooncologists on BRAF-altered tumors, as conventional therapies showed no significant effect, nor prolonged efficiency on the high-grade or low-grade unresectable forms. Nevertheless, tumoral heterogeneity and especially molecular alteration(s) associated with MAPK-pathway abnormalities are not fully understood with respect to how they might lead to the specific dismal prognosis of those gliomas and/or affect their response to targeted therapies. This review is an attempt to provide comprehensive information regarding molecular alterations related to the aggressiveness modulation in BRAF-mutated gliomas and the current knowledge on how to use those targeted therapies in such situations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?
- Author
-
Gomez-Brouchet, Anne, Gilhodes, Julia, Acker, Nathalie Van, Brion, Regis, Bouvier, Corinne, Assemat, Pauline, Gaspar, Nathalie, Aubert, Sebastien, Guinebretiere, Jean-Marc, Marie, Beatrice, Larousserie, Frederique, Entz-Werlé, Natacha, de Pinieux, Gonzague, Mascard, Eric, Gouin, Francois, Brousset, Pierre, Tabone, Marie-Dominique, Jimenez, Marta, Le Deley, Marie-Cecile, Blay, Jean-Yves, Brugieres, Laurence, Piperno-Neumann, Sophie, Rédini, Francoise, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Sarcomes osseux et remodelage des tissus calcifiés - Phy-Os [Nantes - INSERM U1238] (Phy-Os), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université Bretagne Loire (UBL), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de mécanique des fluides de Toulouse (IMFT), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, Institut Gustave Roussy (IGR), Université Paris-Saclay, Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Curie [Paris], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de Hautepierre [Strasbourg], Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Léon Bérard [Lyon], Department of Radiology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France, Département cancer environnement (Centre Léon Bérard - Lyon), University of Nantes, 44007 Nantes, France, Centre National de la Recherche Scientifique - CNRS (FRANCE), Institut National Polytechnique de Toulouse - Toulouse INP (FRANCE), and Université Toulouse III - Paul Sabatier - UT3 (FRANCE)
- Subjects
Osteosarcoma ,Bipotent macrophage ,Macrophage ,Immunothérapie ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,macrophage ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 ,Article ,multiplex ,zoledronic acid ,bipotent macrophage ,osteosarcoma ,osteoclast ,Osteoclast ,Zoledronic acid ,Multiplex ,Cancer - Abstract
Biological and histopathological techniques identified osteoclasts and macrophages as targets of zoledronic acid (ZA), a therapeutic agent that was detrimental for patients in the French OS2006 trial. Conventional and multiplex immunohistochemistry of microenvironmental and OS cells were performed on biopsies of 124 OS2006 patients and 17 surgical (&ldquo, OSNew&rdquo, ) biopsies respectively. CSF-1R (common osteoclast/macrophage progenitor) and TRAP (osteoclast activity) levels in serum of 108 patients were correlated to response to chemotherapy and to prognosis. TRAP levels at surgery and at the end of the protocol were significantly lower in ZA+ than ZA&minus, patients (padj = 0.0011, 0.0132). For ZA+-patients, an increase in the CSF-1R level between diagnosis and surgery and a high TRAP level in the serum at biopsy were associated with a better response to chemotherapy (p = 0.0091, p = 0.0251). At diagnosis, high CD163+ was associated with good prognosis, while low TRAP activity was associated with better overall survival in ZA&minus, patients only. Multiplex immunohistochemistry demonstrated remarkable bipotent CD68+/CD163+ macrophages, homogeneously distributed throughout OS regions, aside osteoclasts (CD68+/CD163&minus, ) mostly residing in osteolytic territories and osteoid-matrix-associated CD68&minus, /CD163+ macrophages. We demonstrate that ZA not only acts on harmful osteoclasts but also on protective macrophages, and hypothesize that the bipotent CD68+/CD163+ macrophages might present novel therapeutic targets.
- Published
- 2021
- Full Text
- View/download PDF
27. Rilpivirine in HIV-1-positive women initiating pregnancy
- Author
-
Frange, Pierre, Tubiana, Roland, Sibiude, Jeanne, Canestri, Ana, Arvieux, Cédric, Brunet-Cartier, Cécile, Cotte, Laurent, Reynes, Jacques, Mandelbrot, Laurent, Warszawski, Josiane, Le Chenadec, Jérôme, Crenn-Hebert, Catherine, Floch-Tudal, Corinne, Mazy, Fabienne, Joras, Marine, Meier, Françoise, Mortier, Emmanuel, Briquet, Catherine, Ichou, Houria, Marty, Laurence, Jabbarian, Hélène, Ceccaldi, Pierre-François, Villemant, Agnès, Zarouk, Virginie, Lefort, Agnès, Ben Salah, Mariam, Hittinger, Gilles, Chamouilli, Jean-Marc, Burle, Christian, Lafeuillade, Alain, Philip, Gisèle, Lambry, Véronique, Medus, Marie, Bachelard, Germaine, Malet, Martine, Dendale-Nguyen, Joëlle, Guimard, Thomas, Guimard, Karine, Brossier, Jean-Pierre, Perre, Philippe, Esnault, Jean-Luc, Aubry, Olivier, Leautez-Nainville, Sophie, Bonnenfant, Valerie, Laine, Laeticia, Martha, Sandrine-Anne, Maurel, Elise, Francoise, Michel, Barat, Muriel, Murger, Patricia, Rouha, Mahfoud, Lévy, Marc, Lumbroso, Philippe, Checoury, Alain, Sahadatu, Osseni, Perfezou, Pascale, Blondin, Gilles, Ansart, Séverine, De Saint Martin, Luc, Le Moine, Philippe, Duthé, Jean-Charles, Daniel, Corinne, Calvez, Christian, Boutaric, Emmanuelle, Rohan, Jennifer, Bauville, Estelle, Dupre, Christelle, Lotton, Pascal, Ouamara-digue, Enora, Poinsignon, Yves, Goussef, Marie, Grelier, Anne, Mousset, Gaetane, Cudeville, Corinne, Niault, Mathilde, Belzic, Isabelle, Moreau, Philippe, Le Coz, Marie-Françoise, Vaillant, Odile Luycx, Guerin-Duplessy, Anne, Mouton-Rioux, Virginie, De Morel, Philippe, Vitrat, Virginie, Tardif, Didier, Gaillat, Jacques, Vanderbergh, Anne, Braig, Suzanne, Clavere, Gaelle, Dehlinger-Paul, Marion, Mohamed, Khaled, Echard, Marie, Camus, Michel, Mulard, Catherine, Fontelonga, Marie-Agnès, Heller-Roussin, Brigitte, Winter, Cécile, Challier, Marion, Debruyne, Elise, Marcou, Valerie, Firtion, Ghislaine, Pannier, Emmanuelle, Costa, Myriam, Launay, Odile, Salmon-Ceron, Dominique, Belkacem, Touria, Bajawi, Youcef, Aubret, Valérie Raynal, Rivaux, Danièle, Elaoun, Neila, Allal, Lahcene, Djoubou, Sandrine, Rahli, Djamila, Moine, Agnès Bourgeois, Valentin, Morgane, Damond, Florence, Huri, Virginie, Vivier, Valérie, Yahia, Fatma Ait, Garrait, Valérie, Hau, Isabelle, Touboul, Claudine, Ratsimbazafy, Lanto, Boiron, Emilie, Elharrar, Brigitte, Labaune, Jean-Marc, Rudigoz, Rene-Charles, Brochier, Corinne, Galvan, Valérie, Ogoudjobi, Stanislas, Elleau, Christophe, Runel-Belliard, Camille, Pistone, Thierry, Fleury, Hervé, Horovitz, Jacques, Sandler, Boris, Roux, Denis, Ragnaud, Jean-Marie, Chabanier, Pierre, Brun, Jean-Luc, Delveaux, Sandrine, Muanza, Blandine, Diallo, Mama Doufari, Lamaury, Isabelle, Sow, Marie-Thérèse, Samar, Ketty, Carpentier, Bénédicte, Osman, Zafer, Dienga, Etienne, Seaume, Hervé, Ducrocq, Sarah, Bailly-Salin, Philippe, Da Silva, Christelle Dusart, Fayolas, Isabelle, Abbal, Julie, Simon-Toulza, Caroline, Truillet, Véronique, Bogner, Noëlle, Chiabrando, Julie, Armand, Evelyne, Cayla, Claudine, Chacé, Anne, Matheron, Isabelle, Richier, Laurent, Miantezila, Joe, Bry, Sandrine, Couderc, Sophie, Narcy, Catherine, Routier, Corinne, Nassar, Rania, Bouldouyre, Marie-Anne, Zakaria, Ahmed, Dauphin, Hélène, Goissen, Céline, Belloy, Marie, Delassus, Jean-Luc, Favret, Véronique, Nemeth, Céline, Partisani, Marialuisa, Entz-Werlé, Natacha, Langer, Bruno, Uettwiller, Françoise, Durand, Myriam, Partizani, MariaLuisa, Cheneau, Christine, Rey, David, Ebel, Edith, Fischer, Patricia, DAVID, Eric, Vayssière, Christophe, Weil, Michèle, Schmitt, Marie Paule, Nisand, Israël, Genet, Philippe, Brault, Dominique, Allisy, Christine, Gerbe, Juliette, Masse, Virginie, Wifaq, Bouchra, Courdavault, Laurence, Gabor, Petra, Tordjeman, Nathalie, Lebrette, Marie-Gisèle, Selleret, Lise, Samama, Déborah, Bolot, Pascal, Khuong-Josses, Marie-Aude, Amel, Mahdi, Bounan, Stéphane, Nourry, Christelle, Andris, Sabine, Blanche, Stephane, Driessen, Marine, Veber, Florence, Fischer, Alain, Rouzioux, Christine, Avettand-Fenoël, Véronique, Mahlaoui, Nizar, Mourey, Marie-Christine, Granier, Michèle, Devidas, Alain, Donnadieu, Anne-Claire, May, Adrien, Chabrol, Amélie, Chevojon, Pierre, Bellahcene, Chahrazede, Sanchez, Audrey, Malbrunot, Claire, Neizelien, Joelle, Agher, Nouara, Pluchart, Claire, Rouger, Christine, Dommergues, Marc, Bonmarchand, Manuela, Shneider, Luminata, Caby, Fabienne, Calin, Ruxandra-Oana, Blanc, Christine, Lupin, Catherine, Pauchard, Michèle, Yangui, Mohamed Amine, Roca, Didier, Todorova, Darina, Laurent, Juliette, Ferry, A., Deschaud, Martine, Blum, Laurent, Chambrin, Véronique, Labrune, Philippe, Clech, Laure, Raho-Moussa, Mariem, Pauly-Ravelly, Isolde, Jault, Thierry, Bouabdallah, Soufiane, Sanchez, Lydie, Sanchez, Anita, Johnson, Ama, Louchard, Agnès, Allouche, Claude, Pathe, Jean-Paul, Lachassine, Eric, Benoist, Laurence, Jeantils, Vincent, Delannoy, Catherine, Benbara, Amélie, Carbillon, Lionel, Borgne, Anne, Moreau, Laurence, PICARD, Fabienne, Karaoui, Leïla, Elbert, Véronique Lefevre, Balaz, Valérie, Bongain, André, Monpoux, Fabrice, Deville, Anne, Galiba, Eliane, Jabbar, Ahmed, Joutel, Martine, Schmidt, Jean-Luc, Decaux, Nathalie, Cravello, Ludovic, Errichiello, Katia, Hubert, Claire, Dollfus, Catherine, Hervé, François, Tabone, Marie-Dominique, Courcoux, Mary-France, Leverger, Guy, Kayem, Gilles, Schnurgier, Aurélie, Jensen, Aurore, Vaudre, Geneviève, Pinquier, Didier, Gromez, Alexis, Pinto-Cardoso, Gaelle, Faye, Albert, Borie, Constance, Levine, Martine, Matheron, Sophie, Marouts, Erianna Bellaton, Boissinot, Christine, Caseris, Marion, Pommelet, Virginie, Morau, Geneviève, Leveille, Sandrine, Boumediene, Marie Astride, Garion, Dominique, Peretti, Delphine, Fourcade, Corinne, Houllier, Marie, Jrad, Ikram, Bourdic, Katia, Monnier, Sylvie, Chirouze, Catherine, Proust, Aurélie, Catteau, Odile, Gardiennet, Quentin, Reliquet, Véronique, Winer, Norbert, Vaucel, Edouard, Rodallec, Audrey, Garnier-André, Elisabeth, Briandet, Claire, Brouard, Jacques, Goubin, Pascale, Beucher, Gaël, Dina, Julia, Demersay, Arnaud Chalvon, Tassi, Sylvie, Lavarenne, Gaelle, Rajguru, Mandovi, Messaoudi, Fabienne, Carré, Nathalie, Rajguru, Mandavi, Bobrie-Moyrand, Claire, Foucaud, Pierre, Bernard, Louis, Maakroun, Zoha, Bourgault, Olivier, Kebaili, Kamila, Bertrand, Yves, Alixe, Véronique, Boyer, Emeline, Billiemaz, Kareen, Fanget, Cécile, Ronat, Véronique, Lesauder, Catherine, Lavastre, Marie Laure, Moulin, Alice, Turquini, Marie-France, Colombani, Dominique, Belgodere, Danièle, Fialaire, Pascale, Proust, Stéphanie, Rehaiem, Sami, Mesnard, Louis, Werner, Evelyne, Dukiel, Nathalie, Desmergers, Baya, Blanc-Ruffat, Isabelle, Maraux, Barbara, Coursol, Anne, Castaneda, Julie, Etienne, Lise, Vintejoux, Emmanuelle, Lalande, Muriel, Segondy, Michel, Guigue, Nelly, De Gennes, Christiane, Clavel, Cyril, Cazassus, François, Walter, Véronique, Mazingue, Françoise, Hammou, Yamina, Lagree, Marion, Paquiez, Odile, D’angelo, Sophie, Boquet, Laurence, Ajana, Faiza, Hatchuel, Yves, Nahri, Imad, Zebelus, Jenny, Genet, Claire, Ducroix-Roubertou, Sophie, Aubrard, Yves, Constanty, Anne, Weinbreck, Pierre, Piet, Emilie, Jacquier, Françoise, Michaud, Christophe, Safwan, Hassan, Boutet, Arnaud, Grand-Courault, Carole, Autret, Fanny, Habibi, Fakher, Azria, Elie, Abdelhadi, Mohamed, Elenga, Narcisse, Bocket, Laurence, Taillet, Françoise, Palenzuela, Gilles, Khadly, Redouane, Pierronnet, Danielle, Dos-Santos, Emmanuelle, David, Selva, Makhloufi, Djamila, Brunel-Dalmas, Florence, Carbonnel-Delalande, Elisabeth, Chiarello, Pierre, Godinot, Matthieu, Gilbert, Sylvie, Massardier, Jérôme, Gauthier-Moulinier, Hélène, Fernandes, Elisabeth, Ranaivojaona, Sata, Chevry, Coralie, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Maladies infectieuses et tropicales [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Centre hospitalier universitaire de Nantes (CHU Nantes), Département de maladies infectieuses, Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Louis Mourier - AP-HP [Colombes], Chirurgie Gynécologique et Obstétrique (CGO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'infectiologie [AP-HP Hôpital Louis Mourier, Colombes], Faculté de Médecine Paris-Diderot [Paris], Université Paris Diderot - Paris 7 (UPD7), Service de Médecine Interne [AP-HP, CHU Beaujon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP], Service de médecine interne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse, Service de pédiatrie, Centre Hospitalier Chalon-sur-Saône William Morey, CH de Lorient, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Université de Brest (UBO)-Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Unité d'hémato-oncologie, CHU Toulouse [Toulouse], Pôle Médico-Chirurgical de Pédiatrie et de Génétique Clinique, Néonatologie, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service de Gynécologie et Obstétrique [Rennes] = Gynaecology [Rennes], CH Bretagne Sud, Centre d'Investigations Biomédicales - Hématologie - Oncologie - Greffes (CIB-HOG), Centre d'Investigations Biomédicales - Hématologie - Oncologie - Greffes-Hopital St Louis, Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Service des Maladies Infectieuses, Centre Hospitalier de la Région d'Annecy (Pringy), University of Warwick [Coventry], Physiopathologie et Pharmacotoxicologie Placentaire Humaine (U1139), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital de la Croix-Rousse [CHU - HCL], Réseau périnatal Aurore, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Bordeaux [Bordeaux], pôle gynécologie-obstétrique et médecine foetale, Laboratoire Rhéologie et Procédés (LRP), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Fédération des Maladies Infectieuses [Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], Centre de compétences des microangiopathies thrombotiques, department of pathology, university hospital, parakou, CHU Pointe-à-Pitre/Abymes [Guadeloupe], Service des Maladies Infectieuses et Tropicales[Point-à-Pitre], Service de Gynécologie-Obstétrique [Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Strasbourg, Développement et physiopathologie de l'intestin et du pancréas, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de gynécologie–obstétrique, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], CHRU Strasbourg, Département d'échographie et de Médecine fœtale, SIHCUS-CMCO, Service de Gynécologie-Obstétrique, CHI Poissy-Saint-Germain, Centre Hospitalier Victor Dupouy, Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Hôpital d'Argenteuil, Centre Hospitalier de Saint-Denis [Ile-de-France], Hôpital Delafontaine, Recherche Epidémiologique en Santé Périnatale et Santé des Femmes et des Enfants (UMR_S 953), Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de microbilogie & unité d'immunologie, hématologie et rhumatologie pédiatriques, Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), Laboratoire de Virologie [CHU Necker], Université Sorbonne Paris Cité (USPC), IFR Necker-Enfants Malades (IRNEM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Médecine néonatale, Centre Hospitalier Sud Francilien, Service de pneumologie [Béclère], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Gynécologie-Obstétrique, Maternité, Chirurgie Gynécologique [CHU Pitié-Salpêtrière], Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Croissance cellulaire, réparation et régénération tissulaires (CRRET), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), Hôpital Antoine Béclère, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Référence Maladies Héréditaires du Métabolisme Hépatique [Hôpital Antoine Béclère - APHP (CRMR), Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Service de gynécologie-obstétrique [Hôpital Jean Verdier], Université Paris 13 (UP13)-Hôpital Jean Verdier [AP-HP], Service de Gynécologie-Obstétrique-Reproduction, Hôpital l'Archet, Service d'Hémato-oncologie Pédiatrique [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Trousseau [APHP], Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Service des maladies infectieuses et tropicales, Service de pédiatrie générale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Institut Pasteur du Laos, Réseau International des Instituts Pasteur (RIIP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service de Gynécologie Obstétrique, Service de Médecine Interne et Immunologie clinique [AP-HP Hôpital Bicêtre], Hôpital Bicêtre, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Service des maladies infectieuses et tropicales [CHU Nantes], Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de virologie [CHU Nantes], Service de Pédiatrie Enfants - Hématologie Oncologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Pédiatrie Médicale [Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gynécologie-Obstétrique et Médecine de la Reproduction [CHU Caen], Service de Virologie [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Médecine Interne et Maladies Infectieuses [Tours], Service d'hématologie : Immuno-Hématologie pédiatrique et transplantation de moelle osseuse, Hôpital Debrousse, CHU Saint-Etienne, Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Médecine Néonatale et Réanimation Pédiatrique, CH René Dubos, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service des Maladies Infectieuses et Tropicales [Hôpital Gustave Dron, Tourcoing], Centre Hospitalier Gustave Dron [Tourcoing], 'Personal Protection Against Vectors' working group (PPAV), PPAV working group, Service des Maladies infectieuses et tropicales [CHU Limoges], CHU Limoges, Equipe de Recherche Médicale Appliquée (ERMA), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), CHU Annecy, Service de Pédiatrie, Centre hospitalier de Saint-Nazaire, EA 3593 Université des Antilles et de la Guyane, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Laboratoire de virologie [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Service d'immunologie, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Centre Hospitalier de Basse-Terre, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Université de Rennes (UR), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Collège de France - Chaire Médecine expérimentale (A. Fischer), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), ANRS CO1/CO11, French national, Viral Hepatitis, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Service des maladies infectieuses et tropicales [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Hôpital des Enfants, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris-Sud - Paris 11 (UP11), CH Evry-Corbeil-CH Evry-Corbeil, CH Evry-Corbeil, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Laboratoire d'Electrotechnique de Lyon (LEL), École Centrale de Lyon (ECL), Université de Lyon-Université de Lyon, Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Université de Limoges (UNILIM)-CHU Limoges, Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
- Subjects
rilpivirine ,viral suppression ,hiv ,hiv-1 ,pregnancy ,conception ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,virology - Abstract
International audience; BackgroundSafety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy.ObjectivesTo describe the characteristics of women initiating pregnancy while on rilpivirine and to compare the outcomes for virologically suppressed subjects continuing rilpivirine until delivery versus switching to an RFC.MethodsIn the ANRS-EPF French Perinatal cohort, we included women on rilpivirine at conception in 2010–18. Pregnancy outcomes were compared between patients continuing versus interrupting rilpivirine. In women with documented viral suppression (
- Published
- 2020
- Full Text
- View/download PDF
28. Involvement of MET/TWIST/APC Combination or the Potential Role of Ossification Factors in Pediatric High-Grade Osteosarcoma Oncogenesis
- Author
-
Entz-Werle, Natacha, Lavaux, Thomas, Metzger, Nadia, Stoetzel, Corinne, Lasthaus, Christelle, Marec, Perrine, Kalita, Chantal, Brugieres, Laurence, Pacquement, Helene, Schmitt, Claudine, Tabone, Marie-Dominique, Gentet, Jean-Claude, Lutz, Patrick, Babin, Annie, Oudet, Pierre, Gaub, Marie Pierre, and Perrin-Schmitt, Fabienne
- Published
- 2007
- Full Text
- View/download PDF
29. SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients
- Author
-
Le Deley, Marie-Cécile, Guinebretière, Jean-Marc, Gentet, Jean-Claude, Pacquement, Hélène, Pichon, Fabienne, Marec-Bérard, Perrine, Entz-Werlé, Natacha, Schmitt, Claudine, Brugières, Laurence, Vanel, Daniel, Dupoüy, Noëlle, Tabone, Marie-Dominique, and Kalifa, Chantal
- Published
- 2007
- Full Text
- View/download PDF
30. Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.
- Author
-
Coutant, Marie, Lhermitte, Benoit, Guérin, Eric, Chammas, Agathe, Reita, Damien, Sebastia, Consuelo, Douzal, Valérie, Gabor, Flaviu, Salmon, Alexandra, Chenard, Marie‐Pierre, Todeschi, Julien, Coca, Andres, Heng, Marie‐Amelie, Vincent, Florence, and Entz‐Werlé, Natacha
- Published
- 2022
- Full Text
- View/download PDF
31. Involvement of the TGFβ pathway in the regulation of α5β1 integrins by caveolin-1 in human glioblastoma
- Author
-
Cosset, Erika C., Godet, Julien, Entz-Werlé, Natacha, Guérin, Eric, Guenot, Dominique, Froelich, Sébastien, Bonnet, Dominique, Pinel, Sophie, Plenat, François, Chastagner, Pascal, Dontenwill, Monique, and Martin, Sophie
- Published
- 2012
- Full Text
- View/download PDF
32. Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low‐grade glioma.
- Author
-
Hamimed, Mourad, Gattacceca, Florence, André, Nicolas, Tresch‐Bruneel, Emmanuelle, Probst, Alicia, Chastagner, Pascal, Pagnier, Anne, De Carli, Emilie, Entz‐Werlé, Natacha, Grill, Jacques, Aerts, Isabelle, Frappaz, Didier, Bertozzi‐Salamon, Anne‐Isabelle, Solas, Caroline, and Leblond, Pierre
- Subjects
VINORELBINE ,GLIOMAS ,CHILD patients ,BODY surface area ,PHARMACOKINETICS ,REGRESSION analysis - Abstract
Aims: There is a crucial need for pharmacokinetic (PK) data on oral vinorelbine (VNR) in the paediatric population. The aim of this work was to assess the PK profile of orally administered VNR in children with recurrent/progressive primary low‐grade glioma (LGG). Methods: A multicentre, open‐label, single‐arm intervention phase II study was conducted. Patients, aged between 6 and 18 years, with histologically confirmed recurrent or progressive primary LGG or non‐documented typical optic pathway tumours, were included. PK parameters were estimated by non‐compartmental analysis using Phoenix WinNonlin® software (version 8.0, Certara, Inc.). The influence of demographic and biological covariates on VNR PK parameters was investigated using a multivariate linear regression analysis. Results: PK analysis included 36 patients with a median age (range) of 11 (6–17) years. Estimates of apparent oral clearance (CL/F), apparent volume of distribution (V/F), half‐life (t1/2) and their between‐subject variability (CV%) at 60 mg m−2 dose level, were 472 L h−1 (51.8%), 7002 L (57.9%) and 10 h (21.0%), respectively. Negligible accumulation of VNR between C1 and C2 was observed. CL/F and V/F were found to increase with body surface area (BSA) (P =.004). Lower area under the concentration–time curve (AUC) levels were observed among children in comparison to adults. Conclusion: Higher doses may be necessary for children with LGG. BSA showed a significant impact on VNR systemic exposure. We believe that our findings will serve as a basis for further studies to better characterize the concentration–response relationships of VNR among paediatric patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas
- Author
-
Entz-Werlé, Natacha, Stoetzel, Corinne, Berard-Marec, Perrine, Kalifa, Chantal, Brugiere, Laurence, Pacquement, Hélène, Schmitt, Claudine, Tabone, Marie-Dominique, Gentet, Jean-Claude, Quillet, Robert, Oudet, Pierre, Lutz, Patrick, Babin-Boilletot, Annie, Gaub, Marie-Pierre, and Perrin-Schmitt, Fabienne
- Published
- 2005
- Full Text
- View/download PDF
34. Prognostic Significance of Allelic Imbalance at the c-kit Gene Locus and c-kit Overexpression by Immunohistochemistry in Pediatric Osteosarcomas
- Author
-
Entz-Werlé, Natacha, Marcellin, Luc, Gaub, Marie-Pierre, Guerin, Eric, Schneider, Anne, Berard-Marec, Perrine, Kalifa, Chantal, Brugiere, Laurence, Pacquement, Helène, Schmitt, Claudine, Tabone, Marie-Dominique, Jeanne-Pasquier, Corinne, Terrier, Philippe, Dijoud, Frédérique, Oudet, Pierre, Lutz, Patrick, and Babin-Boilletot, Annie
- Published
- 2005
- Full Text
- View/download PDF
35. From 3D Cell Culture System to Personalized Medicine in Osteosarcoma
- Author
-
Bornert, Fabien, Gantzer, Justine, Kurtz, Jean-Emmanuel, Entz-Werlé, Natacha, Benkirane-Jessel, Nadia, Hua, Guoqiang, and univOAK, Archive ouverte
- Subjects
3D cell culture ,Osteosarcoma ,Spheroid ,Tumor microenvironment ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Personalized medicine ,[SDV.BC] Life Sciences [q-bio]/Cellular Biology - Abstract
Osteosarcoma is the most common primary bone malignancy presenting typically during childhood and adolescence. However, few improvements of the survival outcomes for osteosarcoma patients have been achieved since the last three decades. Despite the rarity of the diagnosis, the complexity of tumor microenvironment and the genetic heterogeneity of osteosarcoma remain the major obstacles to understanding the mechanisms involved in tumor progression and metastasis, and to screening the pharmacologically active molecules for better drugs. Compared to the 2D cell culture system, 3D cell culture system is much closer to the in vivo physiological condition in tumor. Thus, 3D cell culture system could be a powerful technique to screen therapeutic agent towards personalized medicine in osteosarcoma.
- Published
- 2019
36. Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
- Author
-
Gilardin, Laurent, Delignat, Sandrine, Peyron, Ivan, Ing, Mathieu, Lone, Yu-Chun, Gangadharan, Bagirath, Michard, Baptiste, Kherabi, Yousra, Sharma, Meenu, Pashov, Anastas, Toutirais, Olivier, Loiseau, Pascale, Veyradier, Agnès, Kaveri, Srini, Maillere, Bernard, Coppo, Paul, Lacroix-Desmazes, Sébastien, Chatillon, Jean-François, Hamieh, Mohamad, Bayeux, Florence, Abasq, Claire, Fauquembergue, Emilie, Drouet, Aurélie, Guisier, Florian, Latouche, Jean-Baptiste, Musette, Philippe, Coignard-Biehler, Hélène, Mahlaoui, Nizar, Pilmis, Benoit, Barlogis, Vincent, Brosselin, Pauline, de Vergnes, Nathalie, Debré, Marianne, Malphettes, Marion, Frange, Pierre, Catherinot, Emilie, Pellier, Isabelle, Durieu, Isabelle, Perlat, Antoinette, Royer, Bruno, Le Quellec, Alain, Jeziorski, Eric, Fischer, Alain, Lortholary, Olivier, Aaron+, Laurent, Adoue, Daniel, Aguilar, Claire, Aladjidi, Nathalie, Alcaïs, Alexandre, Amoura, Zahir, Arlet, Philippe, Armari-Alla, Corinne, Bader-Meunier, Brigitte, Bayart, Sophie, Bienvenu, Boris, Blanche, Stéphane, Bodet, Damien, Bonnotte, Bernard, Borie, Raphael, Boutard, Patrick, Briandet, Claire, Brion, Jean-Paul, Brouard, Jacques, Cohen-Beaussant, Sarah, Costes, Laurence, Couderc, Louis-Jean, Cougoul, Pierre, Courteille, Virginie, de Saint Basile, Geneviève, Devoldere, Catherine, Deville, Anne, Donadieu, Jean, Doré, Eric, Dulieu, Fabienne, Edan, Christine, Entz-Werlé, Natacha, Fieschi, Claire, Forestier, Amandine, Fouyssac, Fanny, Gajdos, Vincent, Galicier, Lionel, Gandemer, Virginie, Gardembas, Martine, Gaud, Catherine, Guillerm, Gaelle, Hachulla, Eric, Hamidou, Mohamed, Hermine, Olivier, Hoarau, Cyrille, Humbert, Sebastien, Jaccard, Arnaud, Jacquot, Serge, Jais, Jean-Philippe, Jaussaud, Roland, Jeandel, Pierre-Yves, Kebaili, Kamila, Korganow, Anne-Sophie, Lambotte, Olivier, Lanternier, Fanny, Larroche, Claire, Lascaux, Anne-Sophie, Le Moigne, Emmanuelle, Le Moing, Vincent, Lebranchu, Yvon, Lecuit, Marc, Lefèvre, Guillaume, Lemal, Richard, Te, Valérie Li Thiao, Marie-Cardine, Aude, Silva, Nicolas Martin, Masseau, Agathe, Massot, Christian, Mazingue, Françoise, Merlin, Etienne, Monlibert, Béatrice, Monpoux, Fabrice, Moshous, Despina, Mouthon, Luc, Munzer, Martine, Neven, Bénédicte, Nove-Josserand, Raphaëlle, Oksenhendler, Eric, Ouachée-Chardin, Marie, Oudot, Caroline, Pagnier, Anne, Pasquali, Jean-Louis, Pasquet, Marlène, Perel, Yves, Picard, Capucine, Piguet, Christophe, Plantaz, Dominique, Provot, Johan, Quartier, Pierre, Rieux-Laucat, Frédéric, Roger, Pierre-Marie, Rohrlich, Pierre-Simon, Rubié, Hervé, Salle, Valéry, Sarrot-Reynauld, Françoise, Servettaz, Amélie, Stephan, Jean-Louis, Schleinitz, Nicolas, Suarez, Felipe, Swiader, Laure, Taque, Sophie, Thomas, Caroline, Tournilhac, Olivier, Thumerelle, Caroline, Tron, François, Viallard, Jean-François, Roux, Clément, Tifratene, K, Socie, G., Galambrun, C., Bertrand, Yves, Rialland, F., Jubert, C, Pochon, C, Paillard, C., Sirvent, A., Nelken, B., Vannier, Jean-Pierre, Freycon, C, Beguin, Y, Raus, N, Yakoub-Agha, I., Mohty, M., Dalle, J-H, Michel, Gérard, Pradier, C., Peffault de Latour, R., Rohrlich, P-S, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Greffes d'Epitheliums et Regulation de l'Activation Lymphocytaire, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôptaux universitaires de Strasbourg (HUS), CHU Strasbourg, Institut Stephan Angeloff, Réseau International des Instituts Pasteur (RIIP), Immunogénétique humaine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hématologie Biologique [Béclère], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'Ingénierie et d'Etudes des Protéines, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie pédiatrique, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Unité d'Immunologie Hématologie et Rhumatologie Pédiatrique [Necker, Paris], Hôpital Foch [Suresnes], Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Interne - Centre Hospitalier Lyon Sud, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], CHU Amiens-Picardie, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Collège de France - Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Département de Pédiatrie et maladies infectieuses [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Service d'Hémato-oncologie Pédiatrique, CHU Bordeaux [Bordeaux]-Hôpital Pellegrin, Génétique Humaine des Maladies Infectieuses (Inserm U980), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital de la Tronche, Département d'Immunologie, hématologie et rhumatologie pédiatriques [Hôpital Necker-Enfants malades - APHP], Hématogoie pédiatrique, hôpital Sud, Laboratoire de Mathématiques Nicolas Oresme (LMNO), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Pédiatrie Enfants - Hématologie Oncologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service des Maladies Infectieuses, CHU Grenoble, Service de Pédiatrie Médicale [Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Nutrition et Neurobiologie intégrée (NutriNeuro), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1 (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Hémato-oncologie Pédiatrique [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Trousseau [APHP], Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Département d'Oncologie Pédiatrique [CHU Hautepierre, Strasbourg], Hôpital de Hautepierre [Strasbourg], Immunologie clinique [CHU St-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'Hématologie et d'Oncologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine de l'enfant et de l'adolescent [CHU Rennes], Apoptosis and Tumor Progression (CRCINA-ÉQUIPE 9), Service Hématologie, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de médecine interne [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Cellules Dendritiques, Immunomodulation et Greffes, Université de Tours (UT), Ecole Polytechnique Fédérale de Lausanne (EPFL), Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes, Service d'informatique médicale et biostatistiques [CHU Necker], Université de Reims Champagne-Ardenne (URCA), Institut d’Hémato-Oncologie Pédiatrique, Immunologie et chimie thérapeutiques (ICT), Cancéropôle du Grand Est-Centre National de la Recherche Scientifique (CNRS), service de Médecine Interne et d'Immunologie Clinique [AP-HP Hôpital Bicêtre], Université Paris-Sud - Paris 11 (UP11)-Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), Internal Medicine, Paris, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Catalysis, Synthesis of Biomolecules and Sustainable Development (CSB2D), Centre National de la Recherche Scientifique (CNRS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Biostatistique et de Recherche Clinique (UBRC), Dept of Physiology, McGill University = Université McGill [Montréal, Canada], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut Jean Godinot [Reims], UNICANCER, Service d'Immunopathologie Clinique, Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Service de Pédiatrie médicale - Spécialités médicales [CHU Limoges], CHU Limoges, Service Immuno Hémato-Onco Pédiatrique, Sercice Hématologie, immunologie et oncologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service Hématologie Infantile, Immunogenetics of pediatric autoimmune diseases (Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Département de Médecine Interne, Immunologie clinique et maladies infectieuses [CHU Reims], Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'Hématologie et d'Oncologie pédiatrique, Service d'hématologie clinique, Hôpital Hôtel-Dieu [Paris], Service de pneumologie pédiatrique, Hôpital Jeanne de Flandre [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Protéines de défense des réponses immune et inflammatoire : identification, régulation et rôles physiopathologiques, Médecine Interne, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Pediatrie Debrousse, Hôpital Debrousse, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Combustion, Aérothermique, Réactivité et Environnement (ICARE), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut des Sciences de l'Ingénierie et des Systèmes (INSIS - CNRS), Service d'Hématologie et d'Oncologie Médicale, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service d'hémato-immuno-oncologie pédiatrique [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Etablissement français du sang [Poitiers] (EFS), Public Health Department, Hôpital de l'Archet, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Antoine Béclère, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-CHU Saint Louis [APHP], CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Innate immunity and Immunotherapy (CRCINA - Département INCIT - Equipe 7), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de médecine interne, Hôpital Universitaire d'Amiens, CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Service de médecine interne, hôpital Purpan, Hôpital Sud, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (HOTE GREFFON), Université de Franche-Comté (UFC)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition et Neurobiologie intégrée (NutriNeur0), Ecole nationale supérieure de chimie, biologie et physique-Institut Polytechnique de Bordeaux-Université Sciences et Technologies - Bordeaux 1-Institut National de la Recherche Agronomique (INRA)-Université Bordeaux Segalen - Bordeaux 2, Service d’oncologie hématologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], CIC - Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine de l'enfant et de l'adolescent, CHU Pontchaillou [Rennes]-Hôpital Sud, Apoptose et Progression tumorale (CRCNA / Equipe 9), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche en Santé de l'Université de Nantes (IRS-UN), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Morvan [Brest], Lille Inflammation Research International Center (LIRIC), Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), CHU Toulouse [Toulouse]-Hôpital de Rangueil, Institute of Chemistry for Life and Health Sciences (i-CLEHS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias - Clermont Auvergne (CHELTER), Université Clermont Auvergne (UCA), McGill University, Institut Jean Godinot, CRLCC Jean Godinot, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hématologie pédiatrique, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA), Unité d'Hémato-Oncologie, Hôpital des Enfants, CHU Saint-Etienne, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut des Sciences de l'Ingénierie et des Systèmes (INSIS), CHU Saint-Antoine [APHP], École pratique des hautes études (EPHE), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Chaire Médecine expérimentale (A. Fischer), Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), CHU Pontchaillou [Rennes]-hôpital Sud, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)
- Subjects
Oncology ,medicine.medical_specialty ,Palliative care ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Hematopoietic stem cell transplantation ,Donor lymphocyte infusion ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Treatment Failure ,Child ,ComputingMilieux_MISCELLANEOUS ,Retrospective Studies ,Transplantation ,Acute leukemia ,Chemotherapy ,Leukemia ,business.industry ,Palliative Care ,Hematopoietic Stem Cell Transplantation ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Donor Lymphocytes ,Leukemia, Biphenotypic, Acute ,3. Good health ,Surgery ,Survival Rate ,Leukemia, Myeloid, Acute ,Treatment Outcome ,Lymphocyte Transfusion ,030220 oncology & carcinogenesis ,Acute Disease ,Disease Progression ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,business ,030215 immunology - Abstract
Allogeneic hematopoietic stem cell transplantation (SCT) contributes to improved outcome in childhood acute leukemia (AL). However, therapeutic options are poorly defined in the case of post-transplantation relapse. We aimed to compare treatment strategies in 334 consecutive children with acute leukemia relapse or progression after SCT in a recent 10-year period. Data could be analyzed in 288 patients (157 ALL, 123 AML and 8 biphenotypic AL) with a median age of 8.16 years at transplantation. The median delay from first SCT to relapse or progression was 182 days. The treatment consisted of chemotherapy alone (n=108), chemotherapy followed by second SCT (n=70), supportive/palliative care (n=67), combination of chemotherapy and donor lymphocyte infusion (DLI; n=30), or isolated reinfusion of donor lymphocytes (DLI; n=13). The median OS duration after relapse was 164 days and differed according to therapy: DLI after chemotherapy=385 days, second allograft=391 days, chemotherapy=174 days, DLI alone=140 days, palliative care=43 days. A second SCT or a combination of chemotherapy and DLI yielded similar outcome (hazard ratio (HR)=0.85, P=0.53) unlike chemotherapy alone (HR=1.43 P=0.04), palliative care (HR=4.24, P
- Published
- 2017
- Full Text
- View/download PDF
37. Long‐term follow‐up of children with risk organ‐negative Langerhans cell histiocytosis after 2‐chlorodeoxyadenosine treatment.
- Author
-
Barkaoui, Mohamed‐Aziz, Queheille, Emma, Aladjidi, Nathalie, Plat, Geneviève, Jeziorski, Eric, Moshous, Despina, Lambilliotte, Anne, Kebaili, Kamila, Pacquement, Hélène, Leverger, Guy, Mansuy, Ludovic, Entz‐Werlé, Natacha, Bodet, Damien, Schneider, Pascale, Pagnier, Anne, Lutun, Anne, Gillibert‐Yvert, Marion, Millot, Fréderic, Toutain, Fabienne, and Reguerre, Yves
- Subjects
LANGERHANS-cell histiocytosis ,YEAR ,LYMPHOCYTE count ,LYMPHOPENIA ,IMMUNODEFICIENCY ,DISEASE incidence - Abstract
Summary: The nucleoside analogue, 2‐chlorodeoxyadenosine (2CDA), was reported to be an active treatment for childhood Langerhans cell histiocytosis (LCH) without risk organ (RO−) involvement. However, we lack data on long‐term effects of 2CDA treatment, including the disease reactivation rate, permanent sequelae and long‐term tolerance. This study included 44 children from the French LCH registry, treated for a RO− LCH with 2CDA monotherapy (median number of six courses). The median age at the beginning of 2CDA was 3·6 years (range, 0·3–19·7 years) and the median follow‐up after was 5·4 years (range, 0·6–15·1 years). Objective response to 2CDA was observed in 25 patients (56·8%), while six patients (13·6%) had stable disease and 13 patients (29·5%) exhibited progressive disease. Among patients without progression, only two experienced disease reactivation after 2CDA discontinuation. The five‐year cumulative incidence of disease progression or reactivation after 2CDA therapy initiation was 34·3%. The lymphopenia reported in all cases [72% below absolute lymphocyte count (ALC) of 0·5 G/l], was addressed with appropriate prophylactic measures. Other toxicities above grade 2 were uncommon, and no second malignant neoplasm or neuropathy was reported. The five‐year overall survival was 97·7%. In conclusion, we could confirm that 2CDA monotherapy was a beneficial long‐term therapy for treating patients with RO− LCH. Appropriate management of induced immune deficiency is mandatory. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Bone Formation Deregulations Are the Oncogenesis Keys in Osteosarcomas
- Author
-
Entz-Werlé, Natacha
- Subjects
Medical / Oncology - Abstract
Bone Formation Deregulations Are the Oncogenesis Keys in Osteosarcomas
- Published
- 2012
39. Corrigendum to “Risk adapted chemotherapy for localised Ewing’s sarcoma of bone: The French EW93 study” [Eur. J. Cancer 48 (9) (2012) 1376–1385]
- Author
-
Gaspar, Nathalie, Rey, Annie, Bérard, Perrine Marec, Michon, Jean, Gentet, Jean Claude, Tabone, Marie Dominique, Roché, Henri, Defachelles, Anne Sophie, Lejars, Odile, Plouvier, Emmanuel, Schmitt, Claudine, Bui, Binh, Boutard, Patrick, Taque, Sophie, Munzer, Martine, Vannier, Jean-Pierre, Plantaz, Dominique, Entz-Werle, Natacha, and Oberlin, Odile
- Published
- 2013
- Full Text
- View/download PDF
40. Involvement of the TGFβ pathway in the regulation of α5β1 integrins by caveolin-1 in human glioblastoma.
- Author
-
Cosset, Erika C., Godet, Julien, Entz-Werlé, Natacha, Guérin, Eric, Guenot, Dominique, Froelich, Sébastien, Bonnet, Dominique, Pinel, Sophie, Plenat, François, Chastagner, Pascal, Dontenwill, Monique, and Martin, Sophie
- Abstract
Caveolin-1 plays a crucial role in the development of cancer and its progression. We previously reported that glioblastoma cells expressing low levels of caveolin-1 exerted a more aggressive phenotype than cells expressing high levels. Such phenotype was due to the induction of α
5 β1 integrin subsequent to the depletion of caveolin-1. Caveolin-1 was identified as a transcriptional repressor of α5 β1 integrin. The current study was designed to identify in vitro, the molecular mechanisms by which caveolin-1 controls α5 β1 integrin expression and to determine if a negative correlation between caveolin-1 and α5 β1 integrins also exists in biopsies and xenografted human brain tumors. We showed that depletion of caveolin-1 lead to the activation of the TGFβ/TGFβRI/Smad2 pathway which in turn induced the expression of α5 β1 integrins. We showed that cells expressing the lowest levels of caveolin-1 but the highest levels of α5 β1 integrins and TGFβRI were the most sensitive to a α5 β1 integrin antagonist and a TGFβRI inhibitor. Screening human glioma biopsies and human glioblastoma xenografts, we isolated subgroups with either low levels of caveolin-1 but high levels of α5 β1 integrin and TGFβRI or high levels of caveolin-1 but low levels of α5 β1 integrin and TGFβRI. In conclusion, caveolin-1 controls α5 β1 integrin expression through the TGFβ/TGFβRI/Smad2 pathway. The status of caveolin-1/α5 β1 integrins/TGFβRI might be a useful marker of the tumor evolution/prognosis as well as a predictor of anti-TGFβ or anti-α5 β1 integrin therapies. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
41. Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology.
- Author
-
Thomas, David M., Wilhelm, Miriam, Cleton-Jansen, Anne-Marie, Dirksen, Uta, Entz-Werlé, Natacha, Gelderblom, Hans, Hassan, Bass, Jürgens, Heribert, Koster, Jan, Kovar, Heinrich, Lankester, Arjan C., Lewis, Ian J., Myklebost, Ola, Nathrath, Michaela H.M., Picci, Piero, Whelan, Jeremy S., Hogendoorn, Pancras C. W., and Bielack, Stefan S.
- Published
- 2011
42. The urinary bladder: an extremely rare location of pediatric neuroblastoma
- Author
-
Entz-Werle, Natacha, Marcellin, Luc, Becmeur, François, Eyer, Didier, Babin-Boilletot, Annie, and Lutz, Patrick
- Published
- 2003
- Full Text
- View/download PDF
43. Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas.
- Author
-
Pinto, Lia, Baidarjad, Hanane, Entz-Werlé, Natacha, and Van Dyck, Eric
- Subjects
TELOMERES ,DNA ,MOLECULAR chaperones ,CARCINOGENESIS ,GLIOMAS ,TUMORS in children ,TREATMENT effectiveness ,GENOMICS ,SEX chromatin ,DRUG resistance in cancer cells ,EPIGENOMICS - Abstract
Simple Summary: Pediatric high-grade gliomas (pHGGs) are the leading cause of mortality in pediatric neuro-oncology, due in great part to treatment resistance driven by complex DNA repair mechanisms. pHGGs have recently been divided into molecular subtypes based on mutations affecting the N-terminal tail of the histone variant H3.3 and the ATRX/DAXX histone chaperone that deposits H3.3 at repetitive heterochromatin loci that are of paramount importance to the stability of our genome. This review addresses the functions of H3.3 and ATRX/DAXX in chromatin dynamics and DNA repair, as well as the impact of mutations affecting H3.3/ATRX/DAXX on treatment resistance and how the vulnerabilities they expose could foster novel therapeutic strategies. Despite their low incidence, pediatric high-grade gliomas (pHGGs), including diffuse intrinsic pontine gliomas (DIPGs), are the leading cause of mortality in pediatric neuro-oncology. Recurrent, mutually exclusive mutations affecting K27 (K27M) and G34 (G34R/V) in the N-terminal tail of histones H3.3 and H3.1 act as key biological drivers of pHGGs. Notably, mutations in H3.3 are frequently associated with mutations affecting ATRX and DAXX, which encode a chaperone complex that deposits H3.3 into heterochromatic regions, including telomeres. The K27M and G34R/V mutations lead to distinct epigenetic reprogramming, telomere maintenance mechanisms, and oncogenesis scenarios, resulting in distinct subgroups of patients characterized by differences in tumor localization, clinical outcome, as well as concurrent epigenetic and genetic alterations. Contrasting with our understanding of the molecular biology of pHGGs, there has been little improvement in the treatment of pHGGs, with the current mainstays of therapy—genotoxic chemotherapy and ionizing radiation (IR)—facing the development of tumor resistance driven by complex DNA repair pathways. Chromatin and nucleosome dynamics constitute important modulators of the DNA damage response (DDR). Here, we summarize the major DNA repair pathways that contribute to resistance to current DNA damaging agent-based therapeutic strategies and describe the telomere maintenance mechanisms encountered in pHGGs. We then review the functions of H3.3 and its chaperones in chromatin dynamics and DNA repair, as well as examining the impact of their mutation/alteration on these processes. Finally, we discuss potential strategies targeting DNA repair and epigenetic mechanisms as well as telomere maintenance mechanisms, to improve the treatment of pHGGs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. A DNA Repair and Cell Cycle Gene Expression Signature in Pediatric High-Grade Gliomas: Prognostic and Therapeutic Value.
- Author
-
Entz-Werlé, Natacha, Poidevin, Laetitia, Nazarov, Petr V., Poch, Olivier, Lhermitte, Benoit, Chenard, Marie Pierre, Burckel, Hélène, Guérin, Eric, Fuchs, Quentin, Castel, David, Noel, Georges, Choulier, Laurence, Dontenwill, Monique, Van Dyck, Eric, and Giangaspero, Felice
- Subjects
- *
GLIOMA treatment , *DNA analysis , *PROTEIN metabolism , *BIOMARKERS , *GENETIC mutation , *GLIOMAS , *CELL cycle , *GENE expression , *GENE expression profiling , *CELL lines , *GENE amplification , *CHILDREN - Abstract
Simple Summary: Pediatric high-grade gliomas are incurable brain tumors for which there is a critical need for new therapeutic strategies as well as treatment-predictive biomarkers. This study examined the expression of DNA repair and cell cycle genes in pediatric high-grade gliomas with distinct driving mutations. The aim is to propose a novel classification of these tumors based on sub-groups exposing therapeutic vulnerabilities. Several DNA repair factors were identified that might become new diagnostic markers. Background: Pediatric high-grade gliomas (pHGGs) are the leading cause of mortality in pediatric neuro-oncology, displaying frequent resistance to standard therapies. Profiling DNA repair and cell cycle gene expression has recently been proposed as a strategy to classify adult glioblastomas. To improve our understanding of the DNA damage response pathways that operate in pHGGs and the vulnerabilities that these pathways might expose, we sought to identify and characterize a specific DNA repair and cell-cycle gene expression signature of pHGGs. Methods: Transcriptomic analyses were performed to identify a DNA repair and cell-cycle gene expression signature able to discriminate pHGGs (n = 6) from low-grade gliomas (n = 10). This signature was compared to related signatures already established. We used the pHGG signature to explore already transcriptomic datasets of DIPGs and sus-tentorial pHGGs. Finally, we examined the expression of key proteins of the pHGG signature in 21 pHGG diagnostic samples and nine paired relapses. Functional inhibition of one DNA repair factor was carried out in four patients who derived H3.3 K27M mutant cell lines. Results: We identified a 28-gene expression signature of DNA repair and cell cycle that clustered pHGGs cohorts, in particular sus-tentorial locations, in two groups. Differential protein expression levels of PARP1 and XRCC1 were associated to TP53 mutations and TOP2A amplification and linked significantly to the more radioresistant pHGGs displaying the worst outcome. Using patient-derived cell lines, we showed that the PARP-1/XRCC1 expression balance might be correlated with resistance to PARP1 inhibition. Conclusion: We provide evidence that PARP1 overexpression, associated to XRCC1 expression, TP53 mutations, and TOP2A amplification, is a new theranostic and potential therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology.
- Author
-
Sabo, Amelia-Naomi, Jannier, Sarah, Becker, Guillaume, Lessinger, Jean-Marc, Entz-Werlé, Natacha, Kemmel, Véronique, and Fariña, José B.
- Subjects
DRUG monitoring ,RAPAMYCIN ,PEDIATRIC oncology ,PHARMACOKINETICS ,BODY surface area - Abstract
Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as monotherapy or in combination with other antineoplastic agents. However, in cancer, there is no consensus on sirolimus TDM. In the RAPIRI phase I trial, the combination sirolimus + irinotecan was evaluated as a new treatment for refractory pediatric cancers. Blood sampling at first sirolimus intake (D1) and at steady state (D8), followed by LC/MS
2 analysis, was used to develop a population pharmacokinetic model (Monolix® software). A mono-compartmental model with first-order absorption and elimination best fit the data. The only covariate retained for the final model was "body surface area" (D1 and D8). The model also demonstrated that 1.5 mg/m2 would be the recommended sirolimus dose for further studies and that steady-state TDM is necessary to adjust the dosing regimen in atypical profiles (36.4% of the population). No correlation was found between sirolimus trough concentrations and efficacy and/or observed toxicities. The study reveals the relevance of sirolimus TDM in pediatric oncology as it is needed in organ transplantation. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
46. Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability.
- Author
-
Pierrevelcin, Marina, Fuchs, Quentin, Lhermitte, Benoit, Messé, Melissa, Guérin, Eric, Weingertner, Noelle, Martin, Sophie, Lelong-Rebel, Isabelle, Nazon, Charlotte, Dontenwill, Monique, and Entz-Werlé, Natacha
- Subjects
BONE cancer ,TREATMENT effectiveness ,BONES ,OSTEOSARCOMA ,HYPOXEMIA ,NECROSIS - Abstract
Osteosarcoma is the most frequent primary bone tumor diagnosed during adolescence and young adulthood. It is associated with the worst outcomes in the case of poor response to chemotherapy and in metastatic disease. While no molecular biomarkers are clearly and currently associated with those worse situations, the study of pathways involved in the high level of tumor necrosis and in the immune/metabolic intra-tumor environment seems to be a way to understand these resistant and progressive osteosarcomas. In this review, we provide an updated overview of the role of hypoxia in osteosarcoma oncogenesis, progression and during treatment. We describe the role of normoxic/hypoxic environment in normal tissues, bones and osteosarcomas to understand their role and to estimate their druggability. We focus particularly on the role of intra-tumor hypoxia in osteosarcoma cell resistance to treatments and its impact in its endogenous immune component. Together, these previously published observations conduct us to present potential perspectives on the use of therapies targeting hypoxia pathways. These therapies could afford new treatment approaches in this bone cancer. Nevertheless, to study the osteosarcoma cell druggability, we now need specific in vitro models closely mimicking the tumor, its intra-tumor hypoxia and the immune microenvironment to more accurately predict treatment efficacy and be complementary to mouse models. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
47. Hypoxia Inducible Factors' Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches.
- Author
-
Fuchs, Quentin, Pierrevelcin, Marina, Messe, Melissa, Lhermitte, Benoit, Blandin, Anne-Florence, Papin, Christophe, Coca, Andres, Dontenwill, Monique, and Entz-Werlé, Natacha
- Subjects
OXYGEN metabolism ,CELL proliferation ,CELL lines ,CELLULAR signal transduction ,CEREBRAL anoxia ,GENE expression ,GLIOMAS ,STEM cells ,TUMORS in children ,PATHOLOGIC neovascularization - Abstract
The brain tumor microenvironment has recently become a major challenge in all pediatric cancers, but especially in brain tumors like high-grade gliomas. Hypoxia is one of the extrinsic tumor features that interacts with tumor cells, but also with the blood–brain barrier and all normal brain cells. It is the result of a dramatic proliferation and expansion of tumor cells that deprive the tissues of oxygen inflow. However, cancer cells, especially tumor stem cells, can endure extreme hypoxic conditions by rescheduling various genes' expression involved in cell proliferation, metabolism and angiogenesis and thus, promote tumor expansion, therapeutic resistance and metabolic adaptation. This cellular adaptation implies Hypoxia-Inducible Factors (HIF), namely HIF-1α and HIF-2α. In pediatric high-grade gliomas (pHGGs), several questions remained open on hypoxia-specific role in normal brain during gliomagenesis and pHGG progression, as well how to model it in preclinical studies and how it might be counteracted with targeted therapies. Therefore, this review aims to gather various data about this key extrinsic tumor factor in pHGGs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
48. A very uncommon presentation of bilateral Wilms tumor.
- Author
-
Entz-Werlé, Natacha, Terzic, Joelle, Marcellin, Luc, Christmann, Dominique, Babin-Boilletot, Annie, Fishbach, Michel, Sauvage, Paul, and Lutz, Patrick
- Published
- 2004
- Full Text
- View/download PDF
49. HGG-23. GLUTAMINOLYSIS INVOLVEMENT AND ITS TARGETING IN PEDIATRIC HIGH GRADE GLIOMAS: A NEW WAY OF TREATMENT.
- Author
-
Fuchs, Quentin, Frauli, Mélanie, Ruhland, Elisa, Keime, Celine, Mayer, Stanislas, Namer, Izzie Jacques, Schann, Stephane, Dontenwill, Monique, and Entz-Werlé, Natacha
- Published
- 2019
- Full Text
- View/download PDF
50. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial
- Author
-
Gomez-Brouchet, Anne, Illac, Claire, Gilhodes, Julia, Bouvier, Corinne, Aubert, Sébastien, Guinebretiere, Jean-Marc, Marie, Béatrice, Larousserie, Frédérique, Entz-Werlé, Natacha, de Pinieux, Gonzague, Filleron, Thomas, Minard, Véronique, Minville, Vincent, Mascard, Eric, Gouin, François, Jimenez, Marta, Ledeley, Marie-Cécile, Piperno-Neumann, Sophie, Brugieres, Laurence, and Rédini, Françoise
- Subjects
OSTEOSARCOMA ,MACROPHAGES ,LYMPHOCYTES ,PATIENTS ,THERAPEUTICS - Abstract
The French phase 3 trial (OS 2006) testing zoledronic acid, an osteoclast inhibitor, with chemotherapy and surgery did not improve the outcome of patients with osteosarcoma (OS). To understand this unexpected result, the presence of infiltrating immune cells was investigated in 124 pre-therapeutic biopsies of patients enrolled in the trial. The percentage of CD68/CD163 tumor-infiltrating macrophages (TAMs), CD8+lymphocytes, osteoclasts, and the PD1/PDL-1 checkpoint were assessed by immunohistochemistry. M1/M2 macrophage polarization was characterized by pSTAT1/CMAF staining. The expression of these biomarkers was correlated with clinical outcome. No statistical correlations were found with response to chemotherapy. High CD163 levels (>50% of cells per core; 43.8% of patients) were associated with CMAF nuclear expression and significantly correlated with better overall survival (p= 0.0025) and longer metastasis progression-free survival (MPFS,p= 0.0315) independently of metastatic status (p= 0.002). Only a trend was observed for patients with high CD68-positive cells (p= 0.0582). CD8+staining was positive in >50% of cases with a median staining of 1%. Lower CD8+levels were associated with metastatic disease at diagnosis and the presence of CD8-positive cells significantly correlated with improved overall survival in zoledronate-treated patients (p= 0.0415). PD1/PDL-1 staining was negative in >80% of cases and was not correlated with outcome. Finally, CD163-positive TAMs and CD8 positive cells are crucial prognostic biomarkers in OS, whereas PD1/PDL-1 checkpoint plays a minor role. For the first time, we described a correlation between CD8 positive cells and survival in zoledronate-treated patients. The immunohistochemical analysis of the microenvironment in biopsies may represent a novel tool for therapeutic stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.